Group members

Carlsen A, Steinsbø Ø, Kvaløy JT, Aabakken L, Bolstad N, Warren DJ, Karlsen L, Lundin KEA, Omdal R, Grimstad T (2025)
Optimizing serum adalimumab levels in maintenance therapy via proactive therapeutic drug monitoring improves markers of disease activity in Crohn's disease
Scand J Gastroenterol, 1-12 (in press)
DOI 10.1080/00365521.2025.2573725, PubMed 41105383

Abrantes R, Forcados C, Warren DJ, Santos-Ferreira L, Fleten KG, Senra E, Costa AF, Krpina K, Henrique R, Liberg AM, Rawat P, Gelebart P, McCormack E, Bjørge L, Davidson B, Greiff V, Costea DE, Pinto F, Flatmark K, Gomes C, Inderberg EM, Reis CA, Wälchli S (2025)
Pan-carcinoma sialyl-Tn-targeting expands CAR therapy to solid tumors
Cell Rep Med, 6 (9), 102350
DOI 10.1016/j.xcrm.2025.102350, PubMed 40925376

Grimstad T, Carlsen A, Kvaløy JT, Bolstad N, Warren DJ, Aabakken L, Lundin KEA, Karlsen L, Steinsbø Ø, Omdal R (2025)
Fatigue in Inflammatory Bowel Disease: No Effect of Serum Concentrations of Infliximab, Adalimumab or Anti-Drug Antibodies During Maintenance Therapy
Scand J Immunol, 101 (5), e70029
DOI 10.1111/sji.70029, PubMed 40289444